of afatinib in combination with docetaxel in patients with advanced solid tumors, known to express EGFR/HER2, who had progressed following prior standard therapies. The study defined the MTD of ...

Drugs that target the EGFR protein and block its activity include: afatinib (Gilotrif) dacomitinib (Vizimpro) erlotinib (Tarceva) gefitinib (Iressa) osimertinib (Tagrisso) The most effective ...

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

NICE has turned down Tagrisso in the past in previously-untreated, EGFR-positive NSCLC but has now given its blessing to that use of the drug, as well as for second-line treatment of patients with ...

afatinib and dacotinib; and third-generation EGFR-TKI, osimertinib, that inhibits both EGFR-sensitive mutations and resistant mutation EGFR T790M. ALK inhibitors included first-generation ...